Thymalin and thymosin alpha-1 are the two thymic peptide names a researcher will meet, and they are routinely conflated because both originate from the same small organ and both concern immune function. They come, however, from two different research traditions on two sides of the Cold War, and they are structurally different kinds of material altogether: one is a standardised extract containing many peptides, the other a single defined molecule that became a modern pharmaceutical.
The organ both come from
The thymus is where T lymphocytes mature, and it involutes with age, shrinking and being replaced by fat from puberty onward. By the 1960s and 70s, groups in both the United States and the Soviet Union were extracting peptide fractions from animal thymus on the hypothesis that its secreted factors could restore T-cell function where it was deficient.
The American line ran through Allan Goldstein's laboratory, which produced the partially purified extract thymosin fraction 5 and then isolated individual active components from it. The Soviet line, associated with Khavinson's school in Leningrad, produced its own standardised extract and registered it as a drug. Those two lines are, respectively, where thymosin alpha-1 and thymalin come from.
Thymalin: the standardised extract
Thymalin is a polypeptide fraction extracted from calf thymus, standardised as a preparation rather than purified to a single molecule. It was registered as a pharmaceutical in the Soviet Union in the early 1980s and has been used clinically in Russia since, in settings involving immune suppression, with a literature reporting restoration of T-cell counts and related immune parameters.
The evidentiary caveats are the ones that apply across the Khavinson school's output, which we covered in Epitalon vs Thymalin: most studies are small, most come from the originating network, much is published in Russian-language journals, and independent Western replication is scarce. The defined synthetic dipeptide from the same programme, thymogen, exists precisely because a single molecule is easier to study than an extract. As a research material, thymalin is best understood as a standardised biological fraction with a long clinical history in one country's practice.
Thymosin alpha-1: the defined molecule
Thymosin alpha-1 went the other way. Goldstein's group isolated it from thymosin fraction 5 and published its sequence in 1977: a single, defined 28-amino-acid acidic peptide, N-terminally acetylated. Once sequenced, it could be synthesised, patented and developed like any other drug candidate.
It was, under the name thymalfasin (brand name Zadaxin). It carries marketing approval in a number of countries, principally for chronic hepatitis B and as a vaccine adjuvant, and has been studied in sepsis, oncology support and, during the COVID-19 period, in trials of immune restoration in lymphopenic patients. King and Tuthill's review collects the modern immunopharmacology: enhancement of T-cell differentiation and function through Toll-like receptor pathways on dendritic cells, which is a defined mechanism of a kind thymalin's literature cannot offer for a mixture.
It is worth being precise about one nearby confusion: thymosin alpha-1 is unrelated to thymosin beta-4 beyond the shared family name, a distinction with the same shape as the one we drew in TB-500 vs Thymosin Beta-4. The thymosin label was attached to an extract's components before anyone knew what they were, and the alpha and beta families turned out to be entirely different molecules.
The comparison
Structurally: a standardised multi-peptide extract versus one sequenced, synthesisable molecule. Evidentially: a decades-long single-tradition clinical record versus a modern international dossier with controlled trials and defined mechanism. Practically, for research: an extract is characterised batch to batch as a fraction, while a defined peptide can be verified residue by residue against a certificate of analysis.
None of that makes thymalin uninteresting; the long Russian clinical experience is a genuine data source, and the recent revival of interest in thymic involution has brought both compounds back into discussion. But the two names should never be treated as interchangeable, because they do not even name the same kind of thing.
The takeaway
Thymalin is the Soviet-tradition standardised thymic extract; thymosin alpha-1 is the American-tradition defined 28-residue peptide that became the approved drug thymalfasin. Same organ, same broad hypothesis, different material, different evidence. When a study is cited about either, the first question is which of the two kinds of material it used, and the second is which tradition's methodology stands behind it.
All products are intended for research use only. Not for human consumption. Must be 21 years of age or older to purchase.
References
1. Goldstein, A. L., Low, T. L., McAdoo, M., et al. (1977). Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proceedings of the National Academy of Sciences, 74(2), 725-729.
2. King, R., & Tuthill, C. (2016). Immune modulation with thymosin alpha 1 treatment. Vitamins and Hormones, 102, 151-178.
3. Khavinson, V. Kh. (2002). Peptides and ageing. Neuro Endocrinology Letters, 23(Suppl 3), 11-144.
4. Anisimov, V. N., & Khavinson, V. Kh. (2010). Peptide bioregulation of aging: results and prospects. Biogerontology, 11(2), 139-149.
